Diabetes, Obesity & Metabolism

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

By Tamara Y. Milder, Leah Shepherd, Hans Kristian Pedersen, Michael O. Falster

Study in peoplePopulations

The paper

Tamara Y. Milder, Leah Shepherd, Hans Kristian Pedersen, Michael O. Falster

UNSW Sydney

Diabetes, Obesity & Metabolism, 17 Aug 2026

doi.org/10.1111/dom.71219 PubMed 42608294

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk